Meticulous Research® Unveils In-Depth Report on the Cancer/Tumor Profiling Market Forecasting Growth to $24.70 Billion by 2031

Meticulous Research®, a leading global market intelligence firm, has published its latest comprehensive report titled "Cancer/Tumor Profiling Market Size, Share, Forecast, & Trends Analysis by Biomarker Type (Genetic, Protein), Technology (NGS, PCR, ISH), Cancer Type (Breast, Prostate), Application (Clinical, Research), End User (Pharma, Academic) - Global Forecast to 2031."

Download Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5630

The report provides a detailed analysis of the global cancer/tumor profiling market, highlighting its significant growth trajectory. According to the findings, the market is expected to reach a valuation of $24.70 billion by 2031, with a robust compound annual growth rate (CAGR) of 10.9% over the forecast period.

Key Drivers Fueling Market Growth
The rising prevalence of cancer worldwide remains the primary catalyst for the growth of the cancer/tumor profiling market. Additional factors contributing to this expansion include increasing pharmaceutical R&D investments, the surge in targeted therapies, and the discovery of actionable biomarkers. Moreover, advancements in multi-omics tumor profiling and the declining costs associated with next-generation sequencing (NGS) are further accelerating market growth.

However, market growth is constrained by challenges such as the high capital investment required for NGS technology and prolonged turnaround times for test results. Despite these obstacles, the increasing focus on personalized medicine and the growing adoption of targeted therapies present promising opportunities for market players.

Market Segmentation & Key Insights
The cancer/tumor profiling market is segmented based on biomarker type, technology, cancer type, application, end user, and geography. The report provides a granular analysis of these segments:

Browse in Depth: https://www.meticulousresearch.com/product/cancer-tumor-profiling-market-5630

• Biomarker Type: In 2024, the genetic biomarkers segment is anticipated to dominate the market, accounting for 72% of the total share. This is due to the rising demand for molecular insights into cancer, the growing use of gene-based analyses in clinical care, and the widespread adoption of genetic biomarker testing in determining treatment pathways.

• Technology: Next-generation sequencing (NGS) is projected to hold the largest market share in 2024. NGS offers superior sensitivity for variant detection and reduced sequencing costs, making it a preferred technology for cancer profiling.

• Cancer Type: Among cancer types, breast cancer is expected to lead the market in 2024. Factors such as the increasing incidence of breast cancer, governmental initiatives supporting breast cancer research, rising healthcare expenditures, and reimbursement for technologies like NGS are driving this segment's growth.

• Application: The research applications segment is forecasted to capture the largest share of the market by 2024, fueled by the growing incidence of cancer, the demand for precision medicine, and advancements in biomarker discovery.

• End User: Pharmaceutical and biopharmaceutical companies are poised to dominate the end-user segment, with a 40.9% market share in 2024. Their increasing focus on genomic research, cost-effective sequencing, and precision medicine initiatives are key factors driving this dominance.

Regional Insights
In terms of geography, North America is expected to maintain its leading position in the cancer/tumor profiling market, accounting for 42.7% of the total market share by 2024. This growth is supported by the region's high cancer incidence rates, increased R&D funding, growing demand for precision medicine, and government initiatives that foster cancer research. Europe and Asia-Pacific follow North America in terms of market share, with significant growth potential in emerging markets.

Quick Buy @ https://www.meticulousresearch.com/Checkout/81920399

Leading Market Players
The competitive landscape of the cancer/tumor profiling market is shaped by prominent companies including Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.). These companies are driving innovation in cancer profiling through continuous research and development efforts, strategic partnerships, and acquisitions aimed at enhancing their product portfolios and expanding their market reach.

Related Reports:
Europe Cancer Diagnostics Market - https://www.meticulousresearch.com/product/europe-cancer-diagnostics-market-5787
Point of care Diagnostics Market - https://www.meticulousresearch.com/product/point-of-care-diagnostics-market-4871
In-vitro Diagnostics Market - https://www.meticulousresearch.com/product/ivd-market-4858
IVD Reagents Market - https://www.meticulousresearch.com/product/ivd-reagents-market-5110
Medical Imaging Market - https://www.meticulousresearch.com/product/medical-imaging-market-4950

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email-
sales@meticulousresearch.com
Visit Our Website:
https://www.meticulousresearch.com/
Connect with us on LinkedIn-
https://www.linkedin.com/company/meticulous-research

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

This release was published on openPR.